Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Tappero, S; Barletta, F; Piccinelli, ML; Cano, Garcia, C; Incesu, RB; Morra, S; Scheipner, L; Baudo, A; Tian, Z; Parodi, S; Dell'Oglio, P; Briganti, A; de, Cobelli, O; Chun, FKH; Graefen, M; Longo, N; Ahyai, S; Carmignani, L; Saad, F; Shariat, SF; Suardi, N; Borghesi, M; Terrone, C; Karakiewicz, PI.
Survival of patients with clear cell renal carcinoma according to number and location of organ-specific metastatic sites.
Urol Oncol. 2024; 42(1):22.e23-22.e31
Doi: 10.1016/j.urolonc.2023.08.014
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Ahyai Sascha
- Scheipner Lukas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: The prognostic significance of number and location of organ-specific metastatic sites in treated metastatic clear cell renal carcinoma (ccmRCC) patients is object of debate. The current study aimed to test the association between number and location of organ-specific metastatic sites and overall survival (OS) in ccmRCC. MATERIALS AND METHODS: Within Surveillance, Epidemiology and End Results database (2010-2018), all ccmRCC patients treated with cytoreductive nephrectomy and/or systemic therapy were identified. Kaplan-Meier plots and Cox regression models focused on: A). number of organ-specific metastatic sites: solitary vs. 2 vs. 3 or more; B). solitary organ-specific metastatic sites (lung vs. bone vs. liver vs. brain); C). combinations of 2 and 3 or more different organ-specific metastatic sites. RESULTS: Of 4,527 patients (median OS: 19 months), 3,054 (67%) harbored solitary organ-specific metastatic sites (27 months) vs. 1,153 (25%) combinations of 2 different organ-specific metastatic sites (12 months) vs. 320 (8%) combinations of 3 or more different organ-specific metastatic sites (7 months). In patients with solitary organ-specific metastatic sites, bone metastases portended the longest median OS (median OS: 31 months) vs. liver metastases portended the shortest median OS (16 months). Both were independent predictors of OS (multivariable hazard ratio, bone: 0.87; liver: 1.21). Median OS was similarly poor in patients with combinations of 2 different organ-specific metastatic sites (9-13 months), regardless of their location. The same pattern applied to patients with combinations of 3 or more different organ-specific metastatic sites (6-7 months). CONCLUSIONS: Solitary organ-specific metastatic sites portend the most favorable OS (16-31 months). Solitary bone metastases yield the longest vs. liver metastases the shortest OS. Invariably poor OS applies to combinations of 2 (9-13 months), as well as 3 or more different organ-specific metastatic sites (6-7 months), regardless of their location.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Carcinoma, Renal Cell - pathology
- Kidney Neoplasms - pathology
- Proportional Hazards Models - administration & dosage
- Nephrectomy - methods
- Bone Neoplasms - secondary
- Liver Neoplasms - administration & dosage
- Retrospective Studies - administration & dosage
- Find related publications in this database (Keywords)
- Metastatic clear cell renal carcinoma
- Metastatic locations
- SEER database